STOCK TITAN

BIO-key Trims 2024 Net Loss 49% to $4.3M, Reflecting Higher Gross Margin and Lower Operating Costs, Offsetting 11% Revenue Decrease Due to Business Transition; Hosts Investor Call Today at 10am ET

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

BIO-key International (Nasdaq: BKYI) reported its Q4 and full-year 2024 results, showing significant financial improvements despite an 11% revenue decline to $6.9M. The company's strategic shift away from Swivel Secure products to focus on high-margin software solutions led to a 20% increase in software license revenue to $5.2M.

Key financial highlights include:

  • Net loss reduced by 49% to $4.3M in 2024
  • Gross profit grew to $5.6M in 2024 from $1.4M in 2023
  • Operating expenses reduced by 6% to $9.7M
  • Cash used in operations decreased 23% to $2.91M

Notable achievements include partnerships with California Ed Tech JPA (reaching 195 institutions), National Bank of Egypt deployment, and securing a $910K financial services contract and $500K in defense ministry orders. The company's focus on passwordless, phoneless, and tokenless authentication solutions shows growing market traction, particularly in EMEA regions.

BIO-key International (Nasdaq: BKYI) ha riportato i risultati del quarto trimestre e dell'intero anno 2024, mostrando significativi miglioramenti finanziari nonostante un calo del 11% dei ricavi a $6,9 milioni. Il cambiamento strategico dell'azienda, che si allontana dai prodotti Swivel Secure per concentrarsi su soluzioni software ad alta marginalità, ha portato a un aumento del 20% dei ricavi da licenze software, arrivando a $5,2 milioni.

Tra i principali risultati finanziari si evidenziano:

  • Perdita netta ridotta del 49% a $4,3 milioni nel 2024
  • Profitto lordo aumentato a $5,6 milioni nel 2024 rispetto a $1,4 milioni nel 2023
  • Spese operative ridotte del 6% a $9,7 milioni
  • Liquidità utilizzata nelle operazioni diminuita del 23% a $2,91 milioni

Tra i risultati notevoli ci sono le collaborazioni con California Ed Tech JPA (che coinvolgono 195 istituzioni), il dispiegamento con la National Bank of Egypt e l'ottenimento di un contratto di servizi finanziari da $910.000 e ordini dal ministero della difesa per $500.000. L'attenzione dell'azienda su soluzioni di autenticazione senza password, senza telefono e senza token mostra una crescente trazione nel mercato, in particolare nelle regioni EMEA.

BIO-key International (Nasdaq: BKYI) informó sus resultados del cuarto trimestre y del año completo 2024, mostrando mejoras financieras significativas a pesar de una disminución del 11% en los ingresos a $6.9 millones. El cambio estratégico de la empresa, alejándose de los productos Swivel Secure para centrarse en soluciones de software de alto margen, llevó a un aumento del 20% en los ingresos por licencias de software, alcanzando $5.2 millones.

Los aspectos financieros clave incluyen:

  • Pérdida neta reducida en un 49% a $4.3 millones en 2024
  • Beneficio bruto creció a $5.6 millones en 2024 desde $1.4 millones en 2023
  • Gastos operativos reducidos en un 6% a $9.7 millones
  • Efectivo utilizado en operaciones disminuido en un 23% a $2.91 millones

Logros notables incluyen asociaciones con California Ed Tech JPA (alcanzando 195 instituciones), implementación en el Banco Nacional de Egipto, y la obtención de un contrato de servicios financieros de $910K y órdenes del ministerio de defensa por $500K. El enfoque de la empresa en soluciones de autenticación sin contraseña, sin teléfono y sin token muestra una creciente tracción en el mercado, particularmente en las regiones de EMEA.

BIO-key International (Nasdaq: BKYI)는 2024년 4분기 및 연간 실적을 발표하며, 수익이 11% 감소하여 690만 달러에 달했음에도 불구하고 상당한 재정 개선을 보여주었습니다. 회사는 Swivel Secure 제품에서 고수익 소프트웨어 솔루션으로 전략을 전환하여 소프트웨어 라이센스 수익이 20% 증가하여 520만 달러에 도달했습니다.

주요 재무 하이라이트는 다음과 같습니다:

  • 2024년 순손실이 49% 감소하여 430만 달러에 달함
  • 총 이익이 2023년 140만 달러에서 2024년 560만 달러로 증가함
  • 운영비용이 6% 감소하여 970만 달러에 달함
  • 운영에 사용된 현금이 23% 감소하여 291만 달러에 달함

주목할 만한 성과로는 195개 기관과의 파트너십을 포함한 California Ed Tech JPA, 이집트 국립은행 배포, 91만 달러의 금융 서비스 계약 및 50만 달러의 국방부 주문 확보가 있습니다. 비밀번호, 전화 및 토큰 없는 인증 솔루션에 대한 회사의 집중은 특히 EMEA 지역에서 시장의 관심이 증가하고 있음을 보여줍니다.

BIO-key International (Nasdaq: BKYI) a annoncé ses résultats du quatrième trimestre et de l'année 2024, montrant des améliorations financières significatives malgré une baisse de 11% des revenus à 6,9 millions de dollars. Le changement stratégique de l'entreprise, qui s'éloigne des produits Swivel Secure pour se concentrer sur des solutions logicielles à forte marge, a entraîné une augmentation de 20% des revenus des licences logicielles, atteignant 5,2 millions de dollars.

Les points forts financiers incluent:

  • Perte nette réduite de 49% à 4,3 millions de dollars en 2024
  • Le bénéfice brut a augmenté à 5,6 millions de dollars en 2024 contre 1,4 million de dollars en 2023
  • Les dépenses d'exploitation réduites de 6% à 9,7 millions de dollars
  • Les liquidités utilisées dans les opérations ont diminué de 23% à 2,91 millions de dollars

Parmi les réalisations notables, on trouve des partenariats avec California Ed Tech JPA (atteignant 195 institutions), le déploiement à la Banque nationale d'Égypte, ainsi que la sécurisation d'un contrat de services financiers de 910 000 dollars et des commandes du ministère de la Défense pour 500 000 dollars. L'accent mis par l'entreprise sur des solutions d'authentification sans mot de passe, sans téléphone et sans jeton montre un intérêt croissant sur le marché, en particulier dans les régions EMEA.

BIO-key International (Nasdaq: BKYI) hat die Ergebnisse für das vierte Quartal und das gesamte Jahr 2024 veröffentlicht, die signifikante finanzielle Verbesserungen zeigen, obwohl die Einnahmen um 11% auf 6,9 Millionen USD gesunken sind. Der strategische Wechsel des Unternehmens von Swivel Secure-Produkten hin zu hochmargigen Softwarelösungen führte zu einem Anstieg der Softwarelizenz-Einnahmen um 20% auf 5,2 Millionen USD.

Wichtige finanzielle Highlights umfassen:

  • Der Nettoverlust wurde um 49% auf 4,3 Millionen USD im Jahr 2024 reduziert
  • Der Bruttogewinn stieg im Jahr 2024 auf 5,6 Millionen USD, verglichen mit 1,4 Millionen USD im Jahr 2023
  • Betriebskosten wurden um 6% auf 9,7 Millionen USD gesenkt
  • In den Betrieben verwendetes Bargeld sank um 23% auf 2,91 Millionen USD

Bemerkenswerte Erfolge umfassen Partnerschaften mit California Ed Tech JPA (195 Institutionen erreicht), den Einsatz bei der National Bank of Egypt und die Sicherung eines Finanzdienstleistungsvertrags über 910.000 USD sowie Aufträge des Verteidigungsministeriums über 500.000 USD. Der Fokus des Unternehmens auf passwortlose, telefonlose und tokenlose Authentifizierungslösungen zeigt ein wachsendes Marktinteresse, insbesondere in den EMEA-Regionen.

Positive
  • None.
Negative
  • None.

HOLMDEL, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) solutions featuring passwordless, phoneless and token-less Identity-Bound Biometric (IBB) authentication, announced results for its fourth quarter (Q4’24) and year ended December 31, 2024 (2024). BIO-key’s 2023 results, which were restated and filed with the Company’s 2023 Form 10-K, are reflected in this release for comparison purposes. BIO-key will host an investor call today, Thursday, March 27th at 10:00am ET (details below).

BIO-key CEO, Mike DePasquale commented, “From a strategic standpoint, we substantially strengthened our business in 2024, growing our high-margin software license fee revenue by 20% while exiting our low margin services relationship with Swivel Secure to focus on BIO-key solutions such as PortalGuard IAM and our Identity-Bound Biometrics. This transition away from Swivel Secure licensed solutions resulted in an 11% decline in 2024 revenue, but enabled us to substantially improve overall profitability despite lower revenue.

“We also reduced operating expenses by 6% in 2024 and reduced cash used in operations by 23% to $2.91M in 2024 from $3.79M in 2023. With this transition behind us, we are in a much stronger position to grow and convert top-line revenue into bottom-line contribution.”

Recent Highlights

Mr. DePasquale, continued, “Moving forward, we are seeing very encouraging order demand for our solutions in national defense, financial services and education applications and particular strength in EMEA countries. We are seeing growing interest in our unique capabilities in passwordless, phoneless and tokenless authentication solutions which are best positioned to meet the most pressing security and usability challenges. Our biometric solutions are gaining solid traction in international markets across government, financial services and civil defense applications.

“For example, in Q4’24 we secured a $910K contract with a long-time financial services client to implement our biometric identification technology across its branches. The customer has already enrolled fingerprint biometrics for over 25M end-users and is now upgrading to BIO-key’s “fingerprint-only,” one-to-many identification system. Our solution is expected to trim approximately 30 seconds from each customer interaction, resulting in both an improved customer experience and substantial long-term savings.

“Our longstanding relationship with one of the world’s most esteemed defense ministries saw expanded deployment of our biometric solutions in 2024, a trend we expect to continue in 2025 and beyond. We currently provide authentication and digital security services for over 80,000 ministry personnel and believe that deployment could double or triple in coming years. To date, the ministry has generated $3.3M in total hardware and license revenue, and we are now working under a new long term procurement agreement initiated in Q3 2024.

“This past January, we forged a partnership with the National Bank of Egypt, which is integrating BIO-key’s PortalGuard IAM platform and an industry-leading Identity Governance solution. This project, led by our partner, Raya Information Technology, leverages PortalGuard’s advanced IAM, MFA, and SSO capabilities to secure the digital identities of the bank’s 30,000 employees, and we believe there is potential down the road for this solution to be utilized with its customers.

“BIO-key has also built an established and growing presence in education across over 100 institutions serving over 4M end users. In January, three additional colleges and universities migrated to PortalGuard IDaaS and the Wyoming Department of Education deployed PortalGuard IDaaS, adding a total of over 50,000 IDaaS end users. Building on this momentum, after an extensive RFP and review process, we executed a strategic partnership and Joint Purchase Agreement (JPA) with California’s Education Technology Joint Powers Authority (Ed Tech JPA). The agreement makes PortalGuard an approved IAM solution for the alliance’s 195 K-12 schools and districts, collectively serving over 2.6M students, uniquely positioning our offerings to comply solve Ed Tech JPA member IAM requirements, including compliance with emerging restrictions on the use of personal mobile devices in schools.

“In an effort to seed future market opportunities, in December we announced a strategic collaboration with Fiber Food Systems to explore IAM use cases across the food industry. As part of this agreement, we also acquired shares of Boumarang, Inc. from Fiber in exchange for BIO-key stock. Boumarang is a pioneering force in sustainable, AI-driven, hydrogen-powered, long-range drone technology, a developing market with a clear need for a state-of-the-art IAM solutions. The equity exchange strengthened our balance sheet and paved the way to a strategic collaboration with Guinn Partners to integrate our biometric technology with Guinn’s expertise in IoT and autonomous systems, targeting applications across aerospace, defense, healthcare, logistics and smart cities. These initiatives will take time to develop, but we believe that each of them has the potential to create attractive new commercial opportunities for BIO-key.

“We are off to a strong start in 2025 and believe we are well positioned to deliver improved top- and bottom-line performance. However, given the timing of large customer orders, our financial performance has the potential to fluctuate significantly on a quarter-to-quarter basis. Given increasing interest in our biometric solutions, growing adoption of passwordless, phoneless and tokenless IAM solutions, and the transition we executed in 2024 to a focus on higher-margin BIO-key solutions, we are very optimistic regarding our prospects this year. We remain focused on reducing costs to lower our breakeven level as we continue to explore new markets and strategic partnerships that could advance our path to sustained profitability and positive operating cash flow.”

Financial Results
Please note that the audit our FY2024 financial statements has not been completed by our independent registered public accounting firm as of the date of this press release and are therefore subject to change.

2024 revenues decreased approximately 11% to $6.9M from $7.8M in 2023, largely due to BIO-key’s exit from a Swivel Secure Limited (SSL) distribution agreement and transition to selling BIO-key branded solutions in the EMEA region. The impact of this strategic decision contributed to more high-margin software license fee revenue and a reduction in services revenue from third-party products which carry a much lower gross margin. As a result, 2024 license fee revenue increased 20% to $5.2M in 2024 vs. $4.3M in 2023; service fees declined 50% to $1.1M in 2024 from $2.2 million in 2023; and hardware revenue declined 47% to $0.6M in 2024 from $1.2M in 2023.

In Q4’24 license fee revenue increased 77% to $1.0M; services revenue decreased 28% to $0.3M and hardware revenue declined 88% to $0.1M, also reflecting the impacts of the strategic transition from SSL products and services toward BIO-key solutions.

Gross profit grew to $5.6M in 2024 from $1.4M in 2023, due to a $3.6M hardware reserve taken in 2023 and the impact of growth in higher-margin license sales and a reduction in lower-margin services and hardware revenue. Exiting the SSL agreement contributed to lower costs to support deployments, including software license fees included in sales of Swivel Secure offerings vs. BIO-key’s internally developed software solutions. This resulted in gross profit increasing to $1.2M in Q4’24 vs. negative $95,496 in Q4’23, which included a $1.1M hardware reserve. Both Q4’24 and 2024 gross profit benefited from the sale of $213,005 of fully reserved hardware inventory.

BIO-key reduced its operating expenses by $606,409 to $9.7M in 2024 from $10.3M in 2023, due to a reduction of SG&A costs by $722,563, partially offset by a $116,154 increase in research, development and engineering expense to support new product development. Proactive cost reductions included lower headquarters expenses, sales personnel costs, and marketing show expenses, partially offset by an increase in professional services, principally related to financing activities. BIO-key’s Q4’24 operating expenses were flat year-over-year at $2.6M.

Reflecting greater gross profit and lower operating expenses, BIO-key’s 2024 net loss improved to $4.3M, or ($2.10) per share, from a net loss of $8.7M, or ($15.21) per share, in 2023. Similarly, BIO-key’s Q4’24 net loss improved to $1.6M, or ($0.53) per share, vs. $2.4M, or ($3.99) per share, in Q4’23. 2023 Results included hardware reserves of $3.6M and $1.086M in 2023 and Q4’23, respectively. 2024 results included a positive hardware reserve adjustment of $213,005 in Q4 for the sale of hardware that was previously reserved.

Balance Sheet
As of December 31, 2024, BIO-key had $1.9M of current assets, including $438,000 of cash and cash equivalents, $0.8M of net accounts receivable and due from factor, and $378,000 of inventory. This compares to current assets of $2.6M at December 31, 2023, including approximately $511,000 of cash and cash equivalents, $1.3M of net accounts receivable and due from factor, and $446,000 of inventory.

Conference Call Details

Date / Time:Thursday, March 27th at 10 a.m. ET
Call Dial In #:1-877-418-5460 U.S. or 1-412-717-9594 Int’l
Live Webcast / Replay:Webcast & Replay Link – Available for 3 months.
Audio Replay:1-877-344-7529 U.S. or 1-412-317-0088 Int’l; code 6114035
  

About BIO-key International, Inc. (www.BIO-key.com)

BIO-key is revolutionizing authentication and cybersecurity with biometric-centric, multi-factor identity and access management (IAM) software securing access for over forty million users. BIO-key allows customers to choose the right authentication factors for diverse use cases, including phoneless, tokenless, and passwordless biometric options. Its hosted or on-premise PortalGuard IAM solution provides cost-effective, easy-to-deploy, convenient, and secure access to computers, information, applications, and high-value transactions.

BIO-key Safe Harbor Statement
All statements contained in this press release other than statements of historical facts are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 (the "Act"). The words "estimate," "project," "intends," "expects," "anticipates," "believes" and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management's beliefs, as well as assumptions made by, and information currently available to, management pursuant to the "safe-harbor" provisions of the Act. These statements are not guarantees of future performance or events and are subject to risks and uncertainties that may cause actual results to differ materially from those included within or implied by such forward-looking statements. These risks and uncertainties include, without limitation, our history of losses and limited revenue; our ability to raise additional capital to satisfy working capital needs; our ability to continue as a going concern; our ability to protect our intellectual property; changes in business conditions; changes in our sales strategy and product development plans; changes in the marketplace; continued services of our executive management team; security breaches; competition in the biometric technology industry; market acceptance of biometric products generally and our products under development; our ability to convert sales opportunities to customer contracts; our ability to expand into Asia and other foreign markets; our ability to migrate Swivel Secure customers to BIO-key and Portal Guard offerings; fluctuations in foreign currency exchange rates; delays in the development of products, the commercial, reputational and regulatory risks to our business that may arise as a consequence of the restatement of our financial statements, including any consequences of non-compliance with Securities and Exchange Commission and Nasdaq periodic reporting requirements; our temporary loss of the use of a Registration Statement on Form S-3 to register securities in the future;, any disruption to our business that may occur on a longer-term basis should we be unable to continue to maintain effective internal controls over financial reporting, and statements of assumption underlying any of the foregoing as well as other factors set forth under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023 and other filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as required by law, we undertake no obligation to disclose any revision to these forward-looking statements whether as a result of new information, future events, or otherwise.

Engage with BIO-key

Facebook – Corporate:https://www.facebook.com/BIOkeyInternational/
LinkedIn – Corporate:https://www.linkedin.com/company/bio-key-international
X – Corporate:@BIOkeyIntl 
X – Investors:
@BIO_keyIR
StockTwits:BIO_keyIR
  

Investor Contacts

William Jones, David Collins
Catalyst IR
BKYI@catalyst-ir.com or 212-924-9800

 
BIO-key International, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)
 
 Three Months Ended  Twelve Months Ended 
 December 31,  December 31, 
 2024  2023  2024  2023 
Revenues               
Services$344,444  $478,005  $1,108,506  $2,218,885 
License fees 1,023,701   577,669   5,189,370   4,342,010 
Hardware 94,133   769,427   631,695   1,194,010 
Total revenues 1,462,278   1,825,101   6,929,571   7,754,905 
Costs and other expenses               
Cost of services 73,317   221,940   396,274   861,936 
Cost of license fees 146,122   152,000   589,505   1,174,919 
Cost of hardware 255,927   460,157   516,611   700,231 
Cost of hardware - reserve (213,005)  1,086,500   (213,005)  3,586,500 
Total costs and other expenses 262,361   1,920,597   1,289,385   6,323,586 
Gross profit 1,199,917   (95,496)  5,640,186   1,431,319 
                
Operating Expenses               
Selling, general and administrative 1,815,155   2,040,438   7,140,147   7,862,710 
Research, development and engineering 812,072   587,900   2,511,080   2,394,926 
Total Operating Expenses 2,627,227   2,628,338   9,651,227   10,257,636 
Operating loss (1,427,310)  (2,723,834)  (4,011,041)  (8,826,317)
Other income (expense)               
Interest income 57   5,589   110   11,533 
Gain from sale of asset     20,000       20,000 
Loss on foreign currency transactions (13,004)  (24,000)  (13,004)  (39,000)
Loan fee amortization (60,000)  -   (124,000)  - 
Change in fair value of convertible note -   131,497   -   396,203 
Interest expense (66,932)  (58,890)  (175,755)  (218,270)
Total other income (expense), net (139,879)  74,196   (312,649)  170,466 
                
Loss before provision for income tax (1,567,189)  (2,649,638)  (4,323,690)  (8,655,851)
                
Provision for (income tax) tax benefit -   276,825   -   134,014 
                
Net loss$(1,567,189) $(2,372,813) $(4,323,690) $(8,521,837)
                
Comprehensive loss:               
Net loss$(1,567,189) $(2,372,813) $(4,323,690) $(8,521,837)
Other comprehensive income (loss) – Foreign currency translation adjustment (25,409)  138,029   26,469   265,423 
Comprehensive loss$(1,592,598) $(2,234,784) $(4,297,221) $(8,256,414)
                
Basic and Diluted Loss per Common Share*$(0.53) $(3.99) $(2.10) $(15.21)
                
Weighted Average Common Shares Outstanding*               
Basic and diluted 3,032,240   560,278   2,059,884   560,278 
 
*Periods reflect impact of BIO-key’s 1-for-18 reverse stock split effective December 21, 2023.
 
Please note that the audit our FY2024 financial statements has not been completed by our independent registered public accounting firm as of the date of this press release and are therefore subject to change. 


 
BIO-key International, Inc. and Subsidiaries
CONSOLIDATED BALANCE SHEETS
 
  December 31, 
  2024  2023 
ASSETS        
Cash and cash equivalents $437,604  $511,400 
Accounts receivable, net  718,229   1,201,526 
Due from factor  74,170   99,320 
Inventory, net of reserve  378,307   445,740 
Prepaid expenses and other  278,648   364,171 
Total current assets  1,886,958   2,622,157 
Equipment and leasehold improvements, net  140,198   220,177 
Capitalized contract costs, net  409,426   229,806 
Deposits and other assets  7,976   - 
Operating lease right-of-use assets  73,372   36,905 
Other assets  5,000,000   - 
Intangible assets, net  1,097,630   1,407,990 
Total non-current assets  6,728,602   1,894,878 
TOTAL ASSETS $8,615,560  $4,517,035 
         
LIABILITIES        
Accounts payable $818,187  $1,316,014 
Accrued liabilities  1,278,732   1,305,848 
Note payable  1,525,977   - 
Government loan – BBVA Bank, current portion  132,731   138,730 
Deferred revenue - current  773,267   414,968 
Operating lease liabilities, current portion  24,642   37,829 
Total current liabilities  4,553,536   3,213,389 
Deferred revenue, net of current portion  196,237   28,296 
Deferred tax liability  22,998   22,998 
Government loan – BBVA Bank, net of current portion  44,762   188,787 
Operating lease liabilities, net of current portion  48,994   - 
Total non-current liabilities  312,991   240,081 
TOTAL LIABILITIES  4,866,527   3,453,470 
         
Commitments        
         
STOCKHOLDERS’ EQUITY        
Common stock — authorized, 170,000,000 shares; issued and outstanding; 3,715,483 and 1,032,777 of $.0001 par value at December 31, 2024 and December 31, 2023, respectively  372   103 
Additional paid-in capital  133,030,271   126,047,851 
Accumulated other comprehensive loss  49,290   22,821 
Accumulated deficit  (129,330,900)  (125,007,210)
TOTAL STOCKHOLDERS’ EQUITY  3,749,033   1,063,565 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $8,615,560  $4,517,035 
 
All BIO-key shares issued and outstanding for all periods reflect BIO-key’s 1-for-18 reverse stock split, which was effective December 21, 2023.
 
Please note that the audit our FY2024 financial statements has not been completed by our independent registered public accounting firm as of the date of this press release and are therefore subject to change. 


 
BIO-key International, Inc. and Subsidiaries

CONSOLIDATED STATEMENTS OF CASH FLOWS
 
  Years ended December 31, 
  2024  2023 
         
CASH FLOW FROM OPERATING ACTIVITIES:        
Net loss $(4,323,690) $(8,521,837)
Adjustments to reconcile net loss to cash used for operating activities:        
Depreciation  93,026   75,136 
Amortization of intangible assets and write-off  304,983   354,558 
Interest payable on Note  164,589   - 
Loss on foreign currency  13,004   39,000 
Reserve for inventory  (213,005)  3,586,500 
Allowance for doubtful account  (372,532)  750,000 
Amortization of debt discount  124,000   - 
Amortization of capitalized contract costs  175,900   171,291 
Share based and warrant compensation for employees and consultants  225,245   226,725 
Stock based fees to directors  18,006   39,007 
Bad debt expense  100,000   100,000 
Change in fair value of convertible note  -   (396,203)
Deferred income tax benefit  -   (134,014)
Amortization of operating lease right-of-use assets  79,521   - 
Change in operating assets and liabilities:        
Accounts receivable  855,829   (428,742)
Due from factor  25,150   (49,820)
Capitalized contract costs  (355,520)  (118,028)
Deposits  (7,976)  - 
Right of use asset  (115,988)  160,449 
Inventory  280,438   402,129 
Prepaid expenses and other  85,523   (21,465)
Accounts payable  (502,987)  57,725 
Income tax payable  -   (121,764)
Accrued liabilities  (27,116)  275,561 
Deferred revenue  526,240   (71,288)
Operating lease liabilities  (66,712)  (168,376)
Net cash used for operating activities  (2,914,072)  (3,793,456)
CASH FLOWS FROM INVESTING ACTIVITIES:        
Capital expenditures  (13,047)  (1,000)
Net cash used for investing activities  (13,047)  (1,000)
CASH FLOWS FROM FINANCING ACTIVITIES:        
Proceeds from public offerings      4,296,260 
Repayment of convertible notes      (2,200,000)
Proceeds from the exercise of warrants  1,908,099   320 
Costs incurred for issuance of common stock  (172,350)  (561,367)
Proceeds from issuance of note payable  2,000,000   - 
Repayment of note payable  (762,611)  - 
Repayment of government loan  (150,024)  (119,251)
Proceeds from Employee Stock Purchase Plan  3,740   17,478 
Net cash (used in) provided by financing activities  2,826,854   1,433,440 
Effect of exchange rate changes  26,469   236,894 
NET DECREASE IN CASH AND CASH EQUIVALENTS  (73,796)  (2,124,122)
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR  511,400   2,635,522 
CASH AND CASH EQUIVALENTS, END OF YEAR $437,604  $511,400 
 
All BIO-key shares issued and outstanding for all periods reflect BIO-key’s 1-for-18 reverse stock split, which was effective December 21, 2023.
 
Please note that the audit our FY2024 financial statements has not been completed by our independent registered public accounting firm as of the date of this press release and are therefore subject to change. 



FAQ

What caused BIO-key (BKYI) revenue to decline 11% in 2024?

The revenue decline was due to BIO-key's strategic exit from the Swivel Secure distribution agreement to focus on selling higher-margin BIO-key branded solutions in the EMEA region.

How much did BIO-key's (BKYI) software license revenue grow in 2024?

BIO-key's software license fee revenue increased 20% to $5.2M in 2024 compared to $4.3M in 2023.

What is the value of BIO-key's (BKYI) recent financial services contract?

BIO-key secured a $910K contract with a financial services client to implement biometric identification technology across its branches.

How many institutions does BIO-key's (BKYI) California Ed Tech JPA partnership reach?

The partnership makes BIO-key solutions available to 195 member institutions serving over 2.6M students.

What was BIO-key's (BKYI) cash position at the end of 2024?

As of December 31, 2024, BIO-key had $438,000 in cash and cash equivalents, with total current assets of $1.9M.
Bio-Key Intl Inc

NASDAQ:BKYI

BKYI Rankings

BKYI Latest News

BKYI Stock Data

2.67M
2.58M
30.66%
7.13%
1.12%
Security & Protection Services
Services-prepackaged Software
Link
United States
HOLMDEL